Moosavi Seyed Mohamad, Yazdani-Charati Jamshid, Amini Fatemeh
Psychiatry and Behavioral Sciences Research Center, Addiction Institute, Mazandaran University of Medical Sciences, Sari, Iran.
Department of Biostatistics, School of Health Sciences, Mazandaran University of Medical Sciences, Sari, Iran.
Addict Health. 2019 Jul;11(3):165-172. doi: 10.22122/ahj.v11i3.219.
Methamphetamine (MA) abuse is a serious and costly public health problem worldwide; It also commonly affects the sleep quality. The present study was carried out aiming to evaluate the effectiveness of modafinil versus placebo on sleep pattern in MA withdrawal during an eight-week period.
In a double-blind randomized controlled study, a total of 80 patients with a confirmed diagnosis MA withdrawal were treated with modafinil (200 mg/day). Pittsburgh Sleep Quality Index (PSQI) and Epworth sleepiness scale (ESS) were used to assess sleep pattern in the 1 and 56 days of the study. Analysis of covariance (ANCOVA) was applied to compare the groups. All analyses were performed by using SPSS software with a 5% significance level.
The mean age of the people in the intervention and placebo groups was 32.92 ± 2.06 and 34.08 ± 2.13 years, respectively. The mean scores of ESS decreased from 16.15 ± 4.50 to 9.15 ± 3.34 after the intervention in the modafinil group (P < 0.001), with no significant reduction in the placebo group (P = 0.990). The mean scores of PSQI decreased from 13.88 ± 3.40 to 9.92 ± 3.10 after the intervention in the modafinil group (P < 0.001), however there was no significant reduction in the placebo group (P = 0.980). The value of the Eta effect size of the PSQI and ESS questionnaires was 0.52 and 0.72, respectively. Modafinil was superior to placebo in improving the PSQI and ESS scales in the 56 day of assessment (P < 0.050).
Modafinil improves the sleep quality in patients with MA withdrawal.
甲基苯丙胺（MA）滥用是一个严重且代价高昂的全球公共卫生问题；它还常常影响睡眠质量。本研究旨在评估莫达非尼与安慰剂在八周期间对MA戒断期睡眠模式的有效性。
在一项双盲随机对照研究中，共有80例确诊为MA戒断的患者接受莫达非尼（200毫克/天）治疗。匹兹堡睡眠质量指数（PSQI）和爱泼华嗜睡量表（ESS）用于评估研究第1天和第56天的睡眠模式。采用协方差分析（ANCOVA）比较各组。所有分析均使用SPSS软件进行，显著性水平为5%。
干预组和安慰剂组患者的平均年龄分别为32.92±2.06岁和34.08±2.13岁。莫达非尼组干预后ESS平均得分从16.15±4.50降至9.15±3.34（P<0.001），安慰剂组无显著降低（P = 0.990）。莫达非尼组干预后PSQI平均得分从13.88±3.40降至9.92±3.10（P<0.001），然而安慰剂组无显著降低（P = 0.980）。PSQI和ESS问卷的Eta效应量值分别为0.52和0.72。在评估的第56天，莫达非尼在改善PSQI和ESS量表方面优于安慰剂（P<0.050）。
莫达非尼可改善MA戒断患者的睡眠质量。
